U.S. markets open in 3 minutes

Addex Therapeutics Ltd (ADXN.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
1.47000.0000 (0.00%)
As of 2:58PM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4700
Open1.4600
Bid1.4700 x 0
Ask1.4900 x 0
Day's Range1.4500 - 1.4900
52 Week Range1.4050 - 2.6200
Volume26,439
Avg. Volume28,994
Market Cap50.838M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.4220
Earnings DateMay 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Addex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

      Geneva, Switzerland, September 8, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference (September 13 - 15, 2021). In his presentation, which is scheduled for Monday, September 13, 2021 at 07:00 ET / 13:00 CEST, Mr Dyer will provide a corporate update and discuss recent developments at Adde

    • GlobeNewswire

      Addex to Present at the Swiss Biotech Day

      Geneva, Switzerland, September 2, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present a corporate overview at the Swiss Biotech Day, held September 7, 2021 at the Congress Center Basel, Messeplatz 21, 4058 Basel, Switzerland. Mr. Dyer’s presentation is scheduled for 13:15 in room Montreal. If you would like to schedule a meeting with Mr. Dyer, please

    • GlobeNewswire

      Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update

      Strong cash and cash equivalents position at June 30, 2021 of CHF18.1M ($19.6M)Pivotal dipraglurant PD-LID study initiatedJanssen Pharmaceuticals started Phase 2 study in epilepsy with ADX71149Dipraglurant blepharospasm study on track to start in Q3 2021Completed $11.5M fundraising in January 2021 Geneva, Switzerland, August 5, 2021 - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulatio